PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Isavuconazole for chronic pulmonary aspergillosis: tolerability and TDM-guided dosing

isavuconazolevoriconazoletriazole antifungalschronic pulmonary aspergillosistherapeutic drug monitoringdose optimizationcost analysisretrospective cohortAspergillus fumigatus Infectious Disease / Antimicrobials

Background Information

Standard isavuconazole dosing often overshoots in chronic pulmonary aspergillosis, so early troughs can guide a step down to 100 mg daily.

Isavuconazole may offer better tolerability and lower costs for patients with chronic pulmonary aspergillosis (CPA) compared to voriconazole. 53.8% of patients switched from voriconazole to isavuconazole due to inadequate plasma levels or adverse effects. Isavuconazole required dose adjustments in 50% of patients. This study supports isavuconazole as a viable alternative for long-term CPA management, highlighting its favorable safety and cost profile with therapeutic drug monitoring (TDM). Isavuconazole shows promise for CPA when voriconazole is poorly tolerated or ineffective.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Fama F, Conflitti C, Civati A, Cattaneo D, Torre A, Cossu MV, Borghetti S, Visigalli D, Vimercati S, Antinori S, Riva A, Gori A, Colaneri M, Schiuma M

Citation: Fama F, Conflitti C, Civati A, et al. High frequency of isavuconazole use over voriconazole for chronic pulmonary aspergillosis: a retrospective observational study on tolerability and therapeutic drug monitoring. Antimicrobial agents and chemotherapy. 2026;70(10):e0089226. doi:10.1128/aac.00892-26

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.